Analysts Anticipate OvaScience Inc. (OVAS) to Announce -$0.29 EPS

Equities research analysts predict that OvaScience Inc. (NASDAQ:OVAS) will announce earnings of ($0.29) per share for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for OvaScience’s earnings, with the highest EPS estimate coming in at ($0.28) and the lowest estimate coming in at ($0.32). OvaScience posted earnings per share of ($0.64) during the same quarter last year, which would indicate a positive year over year growth rate of 54.7%. The business is expected to report its next quarterly earnings report on Thursday, March 1st.

According to Zacks, analysts expect that OvaScience will report full year earnings of ($1.48) per share for the current fiscal year, with EPS estimates ranging from ($1.51) to ($1.47). For the next financial year, analysts expect that the company will report earnings of ($1.11) per share, with EPS estimates ranging from ($1.33) to ($0.92). Zacks Investment Research’s EPS calculations are an average based on a survey of research firms that that provide coverage for OvaScience.

A number of analysts have recently weighed in on OVAS shares. Zacks Investment Research cut shares of OvaScience from a “buy” rating to a “hold” rating in a research note on Thursday, October 5th. HC Wainwright restated a “buy” rating and issued a $15.00 price objective on shares of OvaScience in a research note on Monday, November 6th.

Institutional investors have recently modified their holdings of the company. Broadfin Capital LLC acquired a new stake in shares of OvaScience in the second quarter worth $429,000. Sabby Management LLC lifted its stake in shares of OvaScience by 20.2% in the second quarter. Sabby Management LLC now owns 509,300 shares of the biotechnology company’s stock worth $795,000 after buying an additional 85,525 shares during the last quarter. GMT Capital Corp acquired a new stake in shares of OvaScience in the third quarter worth $1,138,000. Jennison Associates LLC lifted its stake in shares of OvaScience by 0.4% in the second quarter. Jennison Associates LLC now owns 2,191,258 shares of the biotechnology company’s stock worth $3,418,000 after buying an additional 7,731 shares during the last quarter. Finally, Legal & General Group Plc lifted its stake in shares of OvaScience by 4,654.1% in the second quarter. Legal & General Group Plc now owns 458,822 shares of the biotechnology company’s stock worth $713,000 after buying an additional 449,171 shares during the last quarter. Institutional investors and hedge funds own 55.30% of the company’s stock.

OvaScience (NASDAQ OVAS) traded up $0.03 during mid-day trading on Friday, reaching $1.52. 631,421 shares of the company’s stock traded hands, compared to its average volume of 554,820. OvaScience has a 12 month low of $1.25 and a 12 month high of $3.42.

TRADEMARK VIOLATION WARNING: This piece was originally posted by Transcript Daily and is owned by of Transcript Daily. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright laws. The correct version of this piece can be read at https://transcriptdaily.com/2017/12/03/analysts-anticipate-ovascience-inc-ovas-to-announce-0-29-eps.html.

About OvaScience

OvaScience, Inc is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue.

Get a free copy of the Zacks research report on OvaScience (OVAS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for OvaScience (NASDAQ:OVAS)

Receive News & Ratings for OvaScience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OvaScience Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply